ClinicalTrials.gg
RecruitingNCT07593222Updated Oct 30, 2026

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

A Phase 1/2 interventional study of Sham iTBS and TMS in Major Depression and Healthy Participants, sponsored by Mclean Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Mclean Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing cycloserine in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Cycloserine · Depressive Disorder, Major.

Planned enrollment
3rd of 10
100 · median 43
Started
2026
with 1 other
Phase 1/2
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
2 of 10
Mclean Hospital

Among the 10 studies testing cycloserine in Depressive Disorder, Major, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 1/2, and was the 9th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies testing cycloserine in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cycloserine

Cycloserine: first FDA approval 1964 (SEROMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cycloserine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Many people with depression do not get better with standard treatments like medications or talk therapy. Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment that uses magnetic pulses to stimulate areas of the brain involved in depression. One form of TMS called intermittent theta burst stimulation (iTBS) is FDA-cleared for depression and takes only 3 minutes to deliver. However, about one-third of patients do not respond to iTBS, and another one-third do not reach full remission. Improving iTBS requires a better understanding of how it works in the brain.

iTBS is thought to work by strengthening connections between brain cells, a process called synaptic plasticity. This process depends on a type of brain receptor called the NMDA receptor. Most of what researchers know about how iTBS affects these connections comes from studies of healthy people. It is not known whether iTBS works the same way in the prefrontal cortex - the brain region targeted during depression treatment - or in people who actually have depression.

This study has two phases.

In Phase 1, both healthy volunteers and people with depression will complete 4 research visits to test how iTBS changes brain activity in the prefrontal cortex and whether medications that increase or decrease NMDA receptor activity change those effects. Each visit involves active or sham (inactive) iTBS combined with one of three study medications: a placebo (inactive pill), d-cycloserine (a medication that increases NMDA receptor activity), or dextromethorphan (a medication that decreases NMDA receptor activity). Brain activity is measured before and after each TMS session using electroencephalography (EEG), a painless test that records electrical signals from the scalp through a cap placed on the head. All participants also complete a brain MRI before beginning study visits for targeting purposes.

In Phase 2, participants with depression will be offered a standard clinical course of 30 daily iTBS sessions (Monday through Friday over 6 weeks). Each session is combined with one blinded study medication (placebo, d-cycloserine, or dextromethorphan) taken daily. Brain activity measurements and standard depression and anxiety questionnaires are collected weekly throughout this phase to track how the brain changes over the course of treatment and whether those changes relate to improvements in symptoms.

Together, the two phases of this study aim to identify the brain mechanism by which iTBS works in people with depression. This knowledge could lead to more effective TMS treatments for people who have not responded to medications or other therapies.

Read the detailed description

Major depressive disorder (MDD) affects an estimated 280 million people worldwide. Approximately one-third of patients do not respond adequately to first-line treatments, a population referred to as having treatment-resistant depression (TRD). Intermittent theta burst stimulation (iTBS) is an FDA-cleared form of repetitive transcranial magnetic stimulation (rTMS) for TRD, but roughly one-third of TRD patients do not respond and another one-third do not achieve full remission. Progress in improving iTBS outcomes is most likely to come from a better understanding of its underlying mechanism of action.

iTBS is hypothesized to produce clinical effects through long-term potentiation (LTP), a process by which repeated stimulation strengthens synaptic connections between neurons. LTP depends critically on N-methyl-D-aspartate receptors (NMDARs). Evidence for this mechanism comes primarily from animal studies and from studies of the motor cortex in healthy human volunteers, where cortical excitability changes can be measured using motor-evoked potentials (MEPs) detected by electromyography. These studies have demonstrated that high-frequency rTMS produces LTP-like effects that are enhanced by NMDAR agonism and blocked by NMDAR antagonism.

However, the relevance of motor cortex findings to the dorsolateral prefrontal cortex (dlPFC) - the clinical target for depression treatment - has not been directly tested. The motor cortex and dlPFC differ substantially in anatomy and interindividual variability. Depression itself is associated with reduced synaptic plasticity, as evidenced by neuropsychological, structural, and molecular findings including reduced expression of NMDAR subunits and synapse-related genes in postmortem prefrontal tissue. Whether LTP-like mechanisms established in the healthy motor cortex translate to the depressed dlPFC cannot be assumed.

The principal investigator's laboratory has produced relevant foundational work. Prior studies demonstrated that the NMDAR partial agonist d-cycloserine (DCS) enhances rTMS-induced LTP-like plasticity in the healthy motor cortex, and that the NMDAR antagonist dextromethorphan (DXM) blocks these effects. A separate randomized clinical trial found that augmenting iTBS with DCS more than doubled remission rates in MDD relative to iTBS plus placebo. A motor cortex study further found that DCS normalized iTBS-induced plasticity in depressed patients, who otherwise showed blunted responses relative to healthy controls, suggesting a plasticity deficit in depression that NMDAR agonism can partially rescue.

TMS-EEG now allows cortical excitability to be measured outside the motor cortex. TMS-evoked potentials (TEPs) are scalp-recorded electrical responses to individual TMS pulses, reflecting summated excitatory and inhibitory postsynaptic potentials from stimulated neuronal populations. Characteristic peaks are named by polarity and latency: positive peaks (P30, P60) are thought to reflect glutamatergic excitatory transmission, while negative peaks (N45, N100) reflect GABAergic inhibitory tone. The P30 peak is the primary outcome measure for this study based on its high correlation with MEP amplitude, its sensitivity to iTBS, and its established reduction by AMPA receptor blockade, consistent with the AMPA receptor upregulation that characterizes LTP. No prior study has combined receptor-modulating pharmacology with rTMS to directly test the synaptic mechanism of iTBS in the dlPFC.

This is a two-phase study. Phase 1 is a within-subject crossover design in both healthy volunteers and participants with MDD, in which each participant completes 4 visits receiving different combinations of active or sham iTBS and oral study medication (placebo, DCS 100 mg, or DXM 150 mg) in randomized counterbalanced order, separated by at least one week. TMS-EEG is used to measure dlPFC excitability before drug administration, after drug administration but before iTBS, and immediately after iTBS. This phase tests whether NMDAR activity is necessary and sufficient for iTBS-induced plasticity in the dlPFC, and compares plasticity responses between healthy and depressed participants.

Phase 2 is a parallel-group design restricted to MDD participants who completed Phase 1, in which participants receive 30 daily weekday iTBS sessions combined with once-daily administration of a single blinded study drug (placebo, DCS 100 mg, or DXM 150 mg). Weekly TMS-EEG assessments track longitudinal change in dlPFC excitability over the treatment course. Phase 2 is considered exploratory.

DCS at 100 mg acts as a partial agonist at the glycine co-agonist site of the NMDA receptor, facilitating NMDAR-mediated synaptic transmission. It reaches near-peak plasma levels within 1-2 hours of oral administration. DXM at 150 mg produces brain concentrations consistent with NMDA receptor blockade in vitro and has been shown in prior studies to block the plasticity after-effects of iTBS, cTBS, tDCS, and other rTMS paradigms. All study medications are dispensed by the McLean Research Pharmacy in blinded, identical capsules.

TMS is delivered using the Nexstim NBS-6 Research System and/or the MagVenture MagPro X100, both FDA-cleared devices with integrated EEG, EMG, and real-time neuronavigation. Individual structural MRI obtained prior to study visits is used for neuronavigation-guided dlPFC targeting and EEG source localization. Resting-state fMRI is collected to enable exploratory post-hoc comparisons of functional connectivity with TEP-measured plasticity.

03

Conditions studied

  • Major Depression
  • Healthy Participants

Keywords

  • TMS
  • depression
  • EEG
  • transcranial magnetic stimulation
  • pharmacologic augmentation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Can safely receive TMS and study drugs
  • Stable medication regimen for one month prior to study participation, and for the duration of the study
  • Not currently receiving TMS, ECT, or ketamine
  • No active safety concerns related to suicidality

Exclusion criteria

Exclusion Criteria:

  • History of seizures or epilepsy
  • History of intracranial pathology or lesions from any etiology
  • History of traumatic brain injury including prolonged loss of consciousness more than 15 min
  • Signs of increased intracranial pressure
  • Any major neurological conditions (ex: recent stroke, tumor, neurodegenerative disorders, etc.)
  • Major medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • Severe migraines that may result in treatment intolerance.
  • Inability to tolerate MRI.
  • Pregnancy
  • Known allergic reaction to d-cycloserine or dextromenthorphan
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Sham comparator
    Sham iTBS + Placebo

    Placebo TMS and placebo drug

    Device: Sham iTBS · Drug: Placebo

  • Placebo comparator
    iTBS + Placebo

    Active TMS and placebo drug

    Device: TMS · Drug: Placebo

  • Experimental
    iTBS + D-cycloserine

    Active TMS and active medication

    Device: TMS · Drug: D-cycloserine

  • Experimental
    iTBS + dextromethorphan

    Active TMS and active medication

    Device: TMS · Drug: Dextromethophan

Interventions

  • DeviceSham iTBS

    ham intermittent theta burst stimulation delivered to the left dorsolateral prefrontal cortex using a sham coil identical in appearance to the active coil. No active magnetic stimulation is delivered. Used to control for the sensory experience of TMS.

    Also known as: Transcranial magnetic stimulation, sham

  • DeviceTMS

    Active intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex combined with oral placebo. iTBS consists of 50 Hz triplets delivered in 2-second bursts at 5 Hz, totaling 600 pulses per session over approximately 3 minutes, delivered using a figure-of-8 coil with real-time neuronavigation at an intensity set relative to each participant's resting motor threshold.

    Also known as: transcranial magnetic stimulation, iTBS, intermittent theta-burst stimulation

  • DrugCycloserineStudies of CycloserineCycloserine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    D-cycloserine at 100 mg acts as a partial agonist at the glycine co-agonist site of the NMDA receptor, facilitating NMDAR-mediated synaptic transmission. It is administered orally approximately 2 hours before iTBS to coincide with near-peak plasma concentration. Compounded as 100 mg capsules.

    Also known as: DCS

  • DrugDextromethorphanStudies of DextromethorphanDextromethorphan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dextromethorphan at 150 mg acts as an NMDA receptor antagonist, blocking NMDAR-mediated synaptic transmission at brain concentrations consistent with in vitro receptor blockade. Administered orally approximately 2 hours before iTBS.

    Also known as: DMO, DXM

  • DrugPlacebo

    Microcrystalline cellulose capsule identical to the drug capsules, administered 2 hours prior to iTBS treatment.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. P30 TMS-Evoked Potential (TEP) Amplitude

    Change in P30 peak amplitude measured by TMS-EEG before and after a single iTBS session. The P30 is a positive deflection occurring approximately 30 milliseconds after a TMS pulse, reflecting glutamatergic excitatory synaptic transmission. Change in P30 amplitude serves as an index of iTBS-induced LTP-like plasticity in the left dorsolateral prefrontal cortex. Comparisons will be made across drug conditions (placebo, d-cycloserine, dextromethorphan), between TMS conditions (active vs. sham), and between participant groups (MDD vs. healthy controls).

    Time frame: From baseline to approximately 10 minutes after cTBS administration, assessed at each of four study visits completed over a minimum of 3 to 6 weeks

Secondary outcomes

  1. Additional TEP Component Amplitudes

    Change in amplitude of additional TEP peaks (N45, P60, and N100) measured before and after iTBS. P60 reflects mixed glutamatergic contributions, N45 reflects GABA-A receptor-mediated inhibitory tone, and N100 reflects GABA-B receptor-mediated inhibitory tone. These components are examined as exploratory markers of drug- and iTBS-induced changes in excitatory and inhibitory synaptic transmission in the dlPFC.

    Time frame: From baseline to approximately 10 minutes after cTBS administration, assessed at each of four study visits completed over a minimum of 3 to 6 weeks

  2. 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR16)

    Self report measure of depressive symptoms. Score range: 0-27. Higher scores indicate more severe symptoms.

    Time frame: From enrollment to the end of treatment at 6 weeks

  3. Patient Health Questionnaire-9 (PHQ-9)

    Self report measure of depressive symptoms. Score range: 0-27. Higher scores indicate more severe symptoms.

    Time frame: From enrollment to the end of treatment at 6 weeks

  4. 7-item Generalized Anxiety Disorder scale (GAD-7)

    Self report measure of anxiety symptoms. Score range: 0-21. Higher scores indicate more severe symptoms.

    Time frame: From enrollment to the end of treatment at 6 weeks

  5. 24-item Behavior and Symptom Identification Scale (BASIS-24)

    Self report measure of mental health and functional difficulties. Range: 0-96. Higher scores indicate more severe symptoms.

    Time frame: From enrollment to the end of treatment at 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ganesh P, Kweon J, Siddiqi SH, Carpenter LL, Brown JC. Comparing synaptic mechanisms of iTBS and 10-Hz rTMS corticomotor plasticity. Transcranial Magn Stimul. 2025 Dec;5:100191. doi: 10.1016/j.transm.2025.100191. Epub 2025 Aug 26. PubMed 41341503 ↗
  • Ganesh P, Kweon J, Tom J, Kim H, Varone G, McGirr A, Brown J. Single-day accelerated TMS with D-cycloserine augmentation for depression: A placebo-controlled trial. Res Sq [Preprint]. 2025 Dec 11:rs.3.rs-7980692. doi: 10.21203/rs.3.rs-7980692/v1. PubMed 41510278 ↗
  • Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmoller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24. PubMed 33243615 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data will be shared through the National Institute of Mental Health Data Archive (NDA) in accordance with NIMH data sharing expectations. Data to be shared will include demographic information, clinical scale scores, and TMS-EEG outcome data. Data will be submitted to the NDA following standard de-identification procedures and will be made available to qualified researchers through the NDA data access request process.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be submitted to the NDA within 1 year of primary study completion or upon publication of primary results, whichever comes first.

Access criteria: Data will be accessible to qualified researchers through the NIMH Data Archive data access request process.

Data sharing details ↗ · nda.nih.gov

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2030, 50 months after the start.

Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's planned 50 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
May 18, 2026
StartActual
Oct 1, 2026was Sep 2026
Primary completionEst.
Dec 1, 2030
CompletionEst.
Jun 30, 2031
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
McLean Hospital is now Recruiting
Oct 30, 2026
Start date
Sep 1, 2026→Oct 1, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    McLean Hospital is now Recruiting
    Start date Sep 1, 2026→Oct 1, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07593222
Lead sponsor
Mclean Hospital
Responsible party
Joshua C. Brown, MD, PhD (Director, TMS Research, Mclean Hospital) — Principal investigator
First posted
May 18, 2026
Start date
Oct 1, 2026
Primary completion
Dec 1, 2030 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Oct 30, 2026

Study contacts

Joshua C Brown, MD, PhD
Contact
jbrown@mclean.harvard.edu
617-855-2944
Prem Ganesh, MS
Contact
pganesh@mgb.org
617-855-2153
Joshua C Brown, MD, PhD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cycloserine · Dextromethorphan

Start the discussion